We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Systemic and Ocular Risks Associated With Therapies for Macular Degeneration: Clarification vs Confusion—Reply

Lesley H. Curtis, PhD; Bradley G. Hammill, MS; Kevin A. Schulman, MD; Scott W. Cousins, MD
Arch Ophthalmol. 2012;130(6):806-807. doi:10.1001/archophthalmol.2012.100.
Text Size: A A A
Published online


In reply

We agree with Friberg and colleagues that caution is always warranted in the conduct and interpretation of nonrandomized treatment comparisons. The important caveats they mention were discussed in our article.1 Additional studies are needed to define the relative treatment benefits and risks of these alternative approaches to a major ocular problem in older adults.

Correspondence: Dr Curtis, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715 (lesley.curtis@duke.edu).

Financial Disclosure: Dr Curtis reported receiving research support from Allergan, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck & Co, Novartis, OSI Eyetech, and sanofi-aventis. Dr Schulman reported receiving research support from Actelion Pharmaceuticals, Allergan, Alnylam Pharmaceuticals, Amgen, Amylin, Arthritis Foundation, Astellas Pharma, Bristol-Myers Squibb, The Duke Endowment, Inspire Pharmaceuticals, Johnson & Johnson, Kureha Corp, Medtronic, Merck & Co, Nabi Biopharmaceuticals, National Patient Advocate Foundation, NovaCardia, Novartis, OSI Eyetech, sanofi-aventis, Scios, Tengion, Theravance, Thomson Healthcare, and Vertex Pharmaceuticals; receiving personal income for consulting ($10 000-$25 000 per year) from McKinsey & Co and the National Pharmaceutical Council; receiving personal income for consulting (<$10 000 per year) from Advanced Health Media, Allergan, American College of Medical Genetics, American Society of Clinical Oncology, Blue Cross and Blue Shield of North Carolina, Certified Medical Representatives Institute, The Commonwealth Fund, East Carolina University, EnablEd, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, LifeMasters Supported SelfCare, Medical Decisions Network, Medtronic, Merck & Co, Novartis, Novo Nordisk, Orexigen Therapeutics, Quintiles, Shire, Social & Scientific Systems, Wallen and Associates, and WebMD; having equity in Alnylam Pharmaceuticals, General Electric, The Manufacturers Life Insurance Co, PepsiCo, and Procter & Gamble; having equity in and serving on the board of directors of Cancer Consultants, Inc; having equity in and serving on the executive board of Faculty Connection, LLC; and having equity in and serving as a managing member of the Physician Education Leadership Institute and Tellus, LLC. Drs Curtis and Schulman have made available online detailed listings of financial disclosures (https://www.dcri.org/about-us/conflict-of-interest/). Dr Cousins reported serving as an investigator/collaborator for clinical research, grantee, and paid scientific adviser/consultant for Genentech and Eyetech.

Funding/Support: This study was supported by a research agreement between OSI Eyetech and Duke University.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2012
Thomas R. Friberg, MS, MD; Veeral Shah, MD; Richard A. Bilonick, PhD
Arch Ophthalmol. 2012;130(6):806-807. doi:10.1001/archophthalmol.2011.1914.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...